Filing Flows › Lenz Therapeutics (LENZ) › Q3 2026 › vs Q2 2026
Lenz Therapeutics (LENZ) Q3 2026 vs Q2 2026 (quarter over quarter)
Lenz Therapeutics's revenue fell $2.1M (-38%) from $5.5M in Q2 2026 to $3.4M in Q3 2026. The biggest changes: License revenue −$3.0M (-79%); Product sales, net +$863K (+50%).
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product sales, net | $2.6M | $1.7M | $863K | +50% |
| License revenue | $785K | $3.8M | −$3.0M | -79% |
| Revenue | $3.4M | $5.5M | −$2.1M | -38% |
| Other income, net | $1.9M | $2.3M | −$308K | -14% |
| Net loss | $31.0M | $31.9M | −$949K | -3% |
| Costs & expenses | $36.3M | $39.7M | −$3.4M | -8% |
| Operating costs | $36.3M | $39.7M | −$3.4M | -8% |
| Cost of revenue | $454K | $280K | $174K | +62% |
| SG&A | $35.8M | $39.4M | −$3.5M | -9% |
| Operating cash sources | $31.0M | $31.9M | −$949K | -3% |
| Depreciation & amortization | $109K | $110K | −$1K | -0.9% |
| Share-based compensation | $4.1M | $4.5M | −$338K | -8% |
| Working capital & other | $4.4M | −$11.4M | $15.8M | — |
| Cash used in operations | $22.3M | $38.7M | −$16.4M | -42% |
| Net loss absorbed | $31.0M | $31.9M | −$949K | -3% |
Questions
How much did Lenz Therapeutics's revenue grow quarter over quarter in Q3 2026?
Lenz Therapeutics's revenue fell $2.1M (-38%) from $5.5M in Q2 2026 to $3.4M in Q3 2026.
What drove Lenz Therapeutics's revenue change in Q3 2026?
License revenue −$3.0M (-79%); Product sales, net +$863K (+50%).